Literature DB >> 2606506

Some characteristics of a secreted chlamydial antigen recognized by IgG from C. trachomatis patient sera.

E S Stuart1, A B Macdonald.   

Abstract

Chlamydia trachomatis serovars release a glycolipid antigen (GLXA) into the culture supernatant during the infective cycle. This antigen is recognized by IgG isolated from humans with a natural chlamydial infection; GLXA may be a major antigenic determinant of chlamydia. It can be immunopurified by molecular shift or affinity chromatography. Silver staining of SDS-PAGE gels demonstrates a pattern of bands that is essentially the same for preparations isolated by either method. GLXA can also be extracted from mature elementary bodies (EB). These preparations show the same pattern of silver staining bands, and the major bands are immunoreactive as shown by Western blot analysis. Isoelectric focusing studies demonstrate that purified GLXA has an acidic pI.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2606506      PMCID: PMC1385532     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  10 in total

1.  Antigens of Chlamydia trachomatis.

Authors:  A B MacDonald
Journal:  Rev Infect Dis       Date:  1985 Nov-Dec

2.  Characterization of an antigen secreted by Chlamydia-infected cell culture.

Authors:  E S Stuart; S M Tirrell; A B MacDonald
Journal:  Immunology       Date:  1987-08       Impact factor: 7.397

3.  Biosynthesis and disulfide cross-linking of outer membrane components during the growth cycle of Chlamydia trachomatis.

Authors:  W J Newhall
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

4.  Isolation and purification of a type-specific antigen from Chlamydia trachomatis propagated in cell culture utilizing molecular shift chromatography.

Authors:  J T Hourihan; T R Rota; A B MacDonald
Journal:  J Immunol       Date:  1980-05       Impact factor: 5.422

Review 5.  Chlamydiae.

Authors:  J Schachter; H D Caldwell
Journal:  Annu Rev Microbiol       Date:  1980       Impact factor: 15.500

6.  Cell-mediated immune responses in owl monkeys (Aotus trivirgatus) with trachoma to soluble antigens of Chlamydia trachomatis.

Authors:  D L Sacks; W J Todd; A B Macdonald
Journal:  Clin Exp Immunol       Date:  1978-07       Impact factor: 4.330

7.  Monoclonal antibody against a genus-specific antigen of Chlamydia species: location of the epitope on chlamydial lipopolysaccharide.

Authors:  H D Caldwell; P J Hitchcock
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

8.  Chlamydia trachomatis elementary bodies possess proteins which bind to eucaryotic cell membranes.

Authors:  W M Wenman; R U Meuser
Journal:  J Bacteriol       Date:  1986-02       Impact factor: 3.490

9.  Identification and properties of chlamydial polypeptides that bind eucaryotic cell surface components.

Authors:  T Hackstadt
Journal:  J Bacteriol       Date:  1986-01       Impact factor: 3.490

10.  Ocular delayed hypersensitivity: a pathogenetic mechanism of chlamydial-conjunctivitis in guinea pigs.

Authors:  N G Watkins; W J Hadlow; A B Moos; H D Caldwell
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

  10 in total
  3 in total

1.  The glycolipid exoantigen derived from Chlamydia muridarum activates invariant natural killer T cells.

Authors:  Ying Peng; Lei Zhao; Sudhanshu Shekhar; Lu Liu; Hong Wang; Qiang Chen; Xiaoling Gao; Xi Yang; Weiming Zhao
Journal:  Cell Mol Immunol       Date:  2012-06-25       Impact factor: 11.530

2.  Examination of chlamydial glycolipid with monoclonal antibodies: cellular distribution and epitope binding.

Authors:  E S Stuart; P B Wyrick; J Choong; S B Stoler; A B MacDonald
Journal:  Immunology       Date:  1991-12       Impact factor: 7.397

3.  Dendrimer-conjugated peptide vaccine enhances clearance of Chlamydia trachomatis genital infection.

Authors:  Ingrid S Ganda; Qian Zhong; Mirabela Hali; Ricardo L C Albuquerque; Francine F Padilha; Sandro R P da Rocha; Judith A Whittum-Hudson
Journal:  Int J Pharm       Date:  2017-05-22       Impact factor: 5.875

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.